賽隆藥業(002898.SZ):擬與中信城開合作建設公司總部及研究院
格隆匯3月23日丨賽隆藥業(002898.SZ)公佈,董事會審議通過了《關於與中信城開珠海投資有限公司合作建設公司總部及研究院的議案》。由於公司缺少商業辦公項目的開發建設經驗和開發資金,為推動項目建設,擬與中信城開珠海投資有限公司合作進行公司總部及研究院開發建設,公司將在保證公司總部及研究院辦公場地的前提下,與中信城開進行合作開發。
項目公司初始註冊資本暫定為人民幣1000萬元,在項目公司設立時以公司認繳出資比例佔註冊資本的51%為前提,剩餘49%可由可由中信城開以及中信城開或其關聯方另行設立的投資基金分別持有。
公司表示,項目建成後,可以滿足公司對經營場地的需求,有利於公司順利開展各項經營活動,有利於公司吸引人才,對公司擴大經營規模從而實現公司的長遠規劃和發展目標及公司可持續發展帶來積極影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.